Become A Featured Company

Big Data, Acquisitions Point the Way for Plant-Based Medicines

Robin Lefferts

August 12th, 2021

App, Top Story

How do you know if plant-based medicines are hitting the mainstream? One indicator might be when tobacco giant Philip Morris International makes a $1.45 billion offer to acquire Vectura, a firm focused on inhaled medicine formulations and devices. The move is part of  PMI’s pivot away from harmful tobacco products and toward “respiratory drug delivery and selfcare wellness,” an approach the company is calling its Beyond Nicotine strategy.

Meanwhile, in a more generalized look at the industry, global spending on botanical and plant-derived medicines is expected to grow from $26.8 billion in 2020 to $37.8 billion in 2030 according to the Visual Capitalist and Refinitiv.

One company at the heart of the movement is RYAH Group Inc. (CSE: RYAH). RYAH makes smart inhalers, pens, and patches that regulate the dosing of plant-based medicines, including cannabis, while feeding information to the company’s AI-powered and patented database. The database and software then helps patients and doctors make informed choices about proper treatments while also providing crucial field data to researchers and growers that helps them hone their efforts.

Big Data, Controlled Dosing Key

If it seems like artificial intelligence is working its way into just about every sector of society, that’s because it is. Small data sets are the bane of scientifically informed decisions, and the computing power to organize, sort, decipher, and learn from large batches of data is essential to many industries. Plant-based medicine, including medical cannabis, certainly fits the profile here. RYAH has assembled what might be the largest database of medical cannabis information in the world, with over 300,000 patients providing info on their treatment choices and experiences.

Combine the huge amount of information with the precision and control offered by RYAH’s smart delivery devices (patches, inhalers, and pens) and truly useful insights can become a reality. It’s not of much use to know that a patient smoked a joint and was able to sleep without knowing exactly how much was taken, the specific characteristics of the strain used, and detailed information about the patient’s experience. All of this is logged through RYAH’s connected system, and the software helps patients and doctors interpret the data in light of both the patient’s own history and the experiences of thousands of other users.

Watch CEO Greg Wagner explain the problems Ryah’s business model is designed to solve

RYAH’s platform is very well suited to clinical trials, the sort of research and development necessary to bring legal cannabis- and plant-based medicines to market. To that end, the company is already involved in a 5 year study in the UK expected to cover tens of thousands of patients suffering from chronic pain. In Italy, the country’s only cannabis-specific clinic is using the inhalers and database to quantify and define patient cannabis use in the country. RYAH also has distribution and development deals in New Zealand and France.

Legitimizing cannabis- and plant-based medicines in the eyes of the mainstream, including patients, doctors, and regulators, requires the strict application of scientific protocols. Many doctors don’t have enough information to comfortably discuss cannabis treatments with patients, and many patients are hesitant due to years of social stigma attached to the plant. Trials and regulators require controlled dosing and repeatable regimens.

To this end, RYAH recently announced a collaboration with the University of Milan to create standard doses for its RYAH Smart Dry Herb Inhalers. “Our collaboration with the University of Milan is expected to afford us an incredible opportunity to, among other things, rigorously map out how cannabis strains behave throughout a full heat-not-burn temperature spectrum at incremental volumes inhaled,” said Jordan Medley, head of product operations at RYAH. “This is a precedent-setting experiment that is expected to generate the data needed to facilitate an accurate milligram dosing experience with dry herb.”

RYAH at the Convergence of High Growth Trends

With more research into cannabis-as-a-medicine, and more jurisdictions around the world opening up medical cannabis programs, the industry is exploding right alongside the general rapid expansion of plant-based medicines. At the same time, big data in healthcare is on a steep growth trajectory, with spending there expected to reach $78 billion by 2027, up from about $20 billion in 2019 according to Emergen Research.

RYAH’s cloud platform, its patented AI-powered software, and the smart devices that feed information to both are right at the center of these high growth trends. It’s certainly a company to watch as plant-based medicines, and especially cannabis-based medicines, hit the mainstream.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading